Adam Steensberg, Zealand Pharma CEO (Betty Laura Zapata/Bloomberg via Getty Images)

March 12, 2025 04:10 AM EDTUpdated 10:23 AM

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

Elizabeth Cairns

Senior biopharma journalist

Zealand Pharma has finally found a partner. And according to the Danish company, the licensing deal it announced with Roche on Wednesday for its amylin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans

Ono licenses rare blood disease drug from Ionis for $280M upfront

Legend to double Carvykti production as it targets blockbuster status

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment

Obesity drug development—still room to grow

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Senior biopharma journalist

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B